Vosevi (Sofosbuvir, Velpatasvir and Voxilaprevir) – HCV | HongKong DengYue Medicine

Vosevi Application Scope

Vosevi is a prescription medication used to treat chronic hepatitis C in adults, especially for those who have previously been treated with other antiviral medicines without success.

Characteristics

• Ingredients: Sofosbuvir, Velpatasvir and Voxilaprevir

• Properties:

  • Sofosbuvir: NS5B RNA polymerase inhibitor

  • Velpatasvir: NS5A inhibitor

  • Voxilaprevir: NS3/4A protease inhibitor

• Packaging Specification:

  • High-density polyethylene (HDPE) bottle with a polypropylene child-resistant closure

  • Containing 28 film-coated tablets, along with a silica gel desiccant

• Storage:

  • Store below 30°C (86°F)

  • Keep in the original container with the desiccant to protect from moisture

  • Keep the bottle tightly closed

• Expiry Date: ​Shelf life is 4 years from the date of manufacture

• Executive Standard: Approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

• Approval Number: U.S. FDA approval granted in July 2017

• Date of Revision: Last revised in 2023

• Manufacturer: Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland

Guidelines for the Use of Vosevi

• Dosage and Administration:

  • Recommended dosage: One tablet taken orally once daily with food

  • Treatment duration: 12 weeks for patients without cirrhosis or with compensated cirrhosis (Child-Pugh A)

• Adverse Reactions:

  Common side effects include:

  • Headache

  • Fatigue

  • Diarrhea

  • Nausea

• Contraindications: Co-administration with rifampin is contraindicated

• Precautions:

  • Risk of hepatitis B virus (HBV) reactivation in patients co-infected with HCV and HBV

  • Serious symptomatic bradycardia when co-administered with amiodarone

  • Use with caution in patients with moderate or severe hepatic impairment (Child-Pugh B or C)

Vosevi Interactions

• Drug Interactions:

  • Avoid co-administration with:

    • Phenytoin

    • Phenobarbital

    • Oxcarbazepine

    • Rifabutin

    • Rifapentine

    • Atazanavir

    • Lopinavir

    • Tipranavir/ritonavir

    • Efavirenz

    • Rosuvastatin

    • Pitavastatin

    • Cyclosporine

  • St. John’s Wort may reduce serum levels of voxilaprevir; avoid concurrent use

  • Antacids may reduce the serum levels of velpatasvir; administer Vosevi at least 4 hours before or after antacids

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.